SecProbe.io

CORRESP
1
filename1.htm

CORRESP

 ROBERT A. FREEDMAN

January 13, 2020

 EMAIL
RFREEDMAN@FENWICK.COM

 Direct Dial (650)
335-7292

CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE OMITTED PORTIONS, WHICH HAVE BEEN REPLACED WITH THE FOLLOWING PLACEHOLDER: “[***].” THE OMITTED PORTIONS HAVE BEEN BRACKETED IN THIS UNREDACTED COPY OF
THE LETTER FOR EASE OF IDENTIFICATION.

 VIA EDGAR AND OVERNIGHT DELIVERY

U.S. Securities and Exchange Commission

 Division of Corporation
Finance

 100 F Street, NE

 Washington, DC 20549

Attention:

 Julia Griffith

 Dietrich King

Christine Tourney

Angela Connell

Re:

 Arcutis Biotherapeutics, Inc.

Registration Statement on Form S-1

Filed January 6, 2020

 File No. 333-235806

 Ladies and Gentlemen:

On behalf of Arcutis Biotherapeutics, Inc. (the “Company”), we submit this letter to assist the staff (the
“Staff”) of the Securities and Exchange Commission (the “Commission”) in its review of the Company’s Registration Statement on Form S-1 (File No. 333-235806) (the “Registration Statement”), to further address comment 10 of the Staff set forth in its letter to the Company dated October 4, 2019, concerning valuation
considerations related to the Company’s equity awards. For the convenience of the Staff, we are providing to the Staff by overnight delivery copies of this letter.

Confidential Treatment Request

 Because
of the commercially sensitive nature of information contained herein, this submission is accompanied by the Company’s request for confidential treatment of selected portions of this letter pursuant to Rule 83 of the Commission’s Rules on
Information and Requests, 17 C.F.R. § 200.83 and the Freedom of Information Act.

 CONFIDENTIAL TREATMENT
REQUESTED BY ARCUTIS BIOTHERAPEUTICS, INC.

 1

 Securities and Exchange Commission

Division of Corporation Finance

 January 13, 2020

 Page
 2

 Preliminary IPO Price Range

We advise the Staff that the Company currently anticipates that it will include a price range in its preliminary prospectus for the proposed
offering that will be between $[***] and $[***] per share (the “Preliminary Price Range”) with a midpoint of anticipated range of approximately $[***]. The Company plans to effect a reverse stock split in connection with its
Offering pursuant to a future amendment of the Company’s certificate of incorporation that will be filed with the Secretary of State of the State of Delaware before filing the Preliminary Prospectus with the Commission (the “Stock
Split”). The share numbers and stock prices set forth in this letter do not reflect the Stock Split and are all pre-split.

The Preliminary Price Range has been determined based, in part, upon current market conditions and the input received from the lead
underwriters on the proposed initial public offering (the “Offering”), including discussions that took place on January 3, 2020 among the senior management of the Company and discussions on January 10, 2019 among
the Pricing Committee of the Company’s Board of Directors (the “Board”) and senior management of the Company. Prior to January 3, 2020, the senior management of the Company had not held formal discussions with the
underwriters regarding a price range for the Offering. Additionally, on December 20, 2019 the senior management of the Company held preliminary and informal discussions with the lead underwriters regarding a potential price range for the
Offering. The Preliminary Price Range does not take into account the current lack of liquidity for the Company’s common stock (“Common Stock”) and assumes a successful Offering in late January 2020 with no weighting
attributed to any other outcome for the Company’s business, such as remaining a privately held company or being sold to a third party.

The Company also notes that it will set forth a bona fide offering price range in a pre-effective
amendment to the Registration Statement (the “Bona Fide Price Range”) prior to the distribution of any preliminary prospectus, but the parameters of the Bona Fide Price Range will be subject to then-current market conditions,
continuing discussions with the underwriters, as well as further business and market developments affecting the Company. The spread within the Bona Fide Price Range will be no more than 20%. The Company expects to include the Bona Fide Price Range
in an amendment to the Registration Statement that would shortly precede the commencement of the Company’s public marketing process, which it anticipates could commence as soon as January 21, 2020.

Fair Value Determinations

 Given the
absence of an active market for the Common Stock, the Board was required to estimate the fair value of the Common Stock at the time of each equity-based award based upon several factors, including the Board’s consideration of input from
management and third-party valuations.

 We supplementally advise the Staff that, as described on pages 96 through 97 of the Registration
Statement, the Board has considered a variety of factors in determining the fair value of the Common Stock for purposes of granting stock options to date. Due to the absence of an active market for the Common Stock, the fair value of its Common
Stock was determined in good faith by the Board, with the assistance and upon the recommendation of management and valuations of the Common Stock prepared by an unrelated third-party valuation firm, based on a number of objective and subjective
factors consistent with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, referred to as the AICPA Practice Aid,
including:

 CONFIDENTIAL TREATMENT
REQUESTED BY ARCUTIS BIOTHERAPEUTICS, INC.

 2

 Securities and Exchange Commission

Division of Corporation Finance

 January 13, 2020

 Page
 3

•

 contemporaneous valuations of its shares of Common Stock;

•

 the prices of each of series of preferred stock sold by the Company to outside investors in arm’s length
transactions, and the rights, preferences and privileges of each of these series of preferred stock relative to its Common Stock;

•

 the Company’s results of operations, financial position and the status of its research and development
efforts;

•

 the composition of the management team and Board;

•

 the material risks related to the business;

•

 the market performance of publicly traded companies in the life sciences and biotechnology sectors;

•

 the likelihood of achieving a liquidity event for the holders of shares of Common Stock, such as a sale of the
company or an initial public offering, given prevailing market conditions;

•

 the lack of marketability of the Common Stock; and

•

 external market conditions affecting the life sciences and biotechnology industry sectors.

A summary of the Company’s stock option grants and the associated valuations for the period starting January 1, 2019 through the
date of this letter are below:

 Grant date

Number
of common
shares
underlying
options
granted(1)

Exercise
price or
purchase
per
share of
Common
Stock

Estimated
fair value
per share
of
Common
Stock

 Valuation date

 March 5, 2019

373,750

$
0.84

$
0.84

August 31, 2018

 March 13, 2019

1,767,200

$
0.84

$
0.84

August 31, 2018

 May 14, 2019

550,000

$
0.84

$
0.84

August 31, 2018

 June 11, 2019

240,000

$
0.84

$
0.84

August 31, 2018

 October 18, 2019

340,000

$
3.26

$
3.26

September 25, 2019

 October 28, 2019

580,000

$
3.26

$
3.26

September 25, 2019

 November 20, 2019

1,083,500

$
3.26

$
3.26

September 25, 2019

 December 18, 2019(2)

26,500

$
0.29

$
3.26

September 25, 2019

(1)
 All grants are stock option grants unless otherwise indicated.

(2)
 Restricted stock grant.

Major company events that indicated an increase in value were used as inflection points to obtain additional financing, as such valuations
were performed in conjunction with issuance of convertible preferred stock, which were determined to be arms-length transactions. The valuation performed on August 31, 2018 was based on the Company’s Series B convertible preferred stock
financing (the “Series B Financing”), which contemplated increases in value associated with the AstraZeneca license agreement entered into in July 2018, as well as Company progress to that date, including the results of the
Company’s

 CONFIDENTIAL TREATMENT
REQUESTED BY ARCUTIS BIOTHERAPEUTICS, INC.

 3

 Securities and Exchange Commission

Division of Corporation Finance

 January 13, 2020

 Page
 4

Phase 2a study in psoriasis. Major Company events which reflected additional increases in value after the August 31, 2018 valuation were reflected in the valuation performed as of
September 25, 2019 and included the Company’s Series C convertible preferred stock financing (the “Series C Financing”), which closed in October 2019 but was included in the analysis, the results of the Phase 2b
study in psoriasis, completed in July 2019, as well as the Company’s progress towards an initial public offering (“IPO”) that started with the organizational meeting in August 2019, which allowed the reasonable
estimation of the form and timing of potential liquidity events.

 The dates of the valuations were not contemporaneous with the grant
dates of the Company’s equity awards. Therefore, the Company considered the amount of time between the valuation date and the grant date to determine whether to use the latest Common Stock valuation for the purposes of determining the estimated
fair value of its Common Stock for financial reporting purposes. For grants made between the dates of the valuations, when the Board determined that there had not been any significant changes in the equity value of the Company, it used the fair
value of the Common Stock as of the date of the most current valuation report, taking into consideration the factors noted above.

 Summary of Method
Used by Valuation Date

 For the August 31, 2018 valuation, the Company utilized the Backsolve Method, which utilized the recent
Series B Financing and applied the Black-Scholes option pricing method (“OPM”), which is an accepted valuation method under the AICPA Practice Guide, for determining the fair value of its Common Stock. The OPM values each
equity class by creating a series of call options on the equity value, with exercise prices based on the liquidation preferences, participation rights and strike prices of derivatives. The Backsolve Method was utilized as the Company determined that
the Series B Financing was an arms-length transaction and because the Company could not reasonably estimate the form and timing of potential liquidity events as of the time of grant for awards issued prior to October 18, 2019. At each grant
date, the Board considered whether any events occurred that would trigger any material changes to the business or would require adjustment to the fair value of its Common Stock. For the September 25, 2019 valuation, the Company has applied the
hybrid method for determining the fair value of its Common Stock, as discussed below. The Company elected to utilize the hybrid method as estimates regarding potential outcomes were considered reasonable.

At each grant date, the Board considered whether any events occurred that would trigger any material changes to the estimated fair value of
the business from the previous valuation date. Under the hybrid method, the per share value of the Common Stock is estimated based upon the probability-weighted present value of expected future equity values for the Common Stock, under various
possible future liquidity event scenarios, in light of the rights and preferences of each class of stock, discounted for a lack of marketability.

The restricted stock award granted on December 18, 2019 was issued in replacement of vested options that had expired with a purchase
price that was less than the fair market value on the date of grant. The difference between the purchase price and fair market value will be recognized as compensation expense in the fourth quarter of fiscal 2019.

 CONFIDENTIAL TREATMENT
REQUESTED BY ARCUTIS BIOTHERAPEUTICS, INC.

 4

 Securities and Exchange Commission

Division of Corporation Finance

 January 13, 2020

 Page
 5

 Summary of Most Recent Valuation

On October 18, 2019, the Company determined the fair value of its Common Stock to be $3.26 per share (the “Estimated Fair Value
Per Share”). This determination was based in part on a third-party valuation conducted as of September 25, 2019 (the “September 25 Valuation”) utilizing the hybrid method.
For purposes of the Estimated Fair Value Per Share, the Company anticipated a [***]% probability of an IPO event to occur in January 2020 and a [***]% probability of an IPO event to occur in December 2020. However, the likelihood of the Company
consummating an IPO in the near-term was not certain, and due to market uncertainty and various strategic business factors, the Company also considered alternative scenarios for the Company. Ultimately, the Company determined the Estimated Fair
Value Per Share assuming three potential future events:

(i)
 an IPO in January 2020 (the “Early IPO”);

(ii)
 an IPO in December 2020 (the “Late IPO”); and

(iii)
 the Company continuing to remain privately held (“Stay Private”).

 The Board, in consultation with management, weighted the aggregate probability of an IPO at [***]% and Stay Private
scenario at [***]%. The Board also determined that it was more likely that an IPO would occur in January 2020 as compared to potential alternative IPO timing scenarios occurring in December 2020. The Company believes that the potential future events
used in the September 25 Valuation and the probability weighting of each future event was appropriate at the time, in light of the Company’s stage of development, operating results, its prospects for an IPO in the near term, general
conditions in the capital markets, including with respect to IPOs, and the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The timing of these future liquidity event scenarios was
determined based primarily on input from the Board and management.

 Discussion of Estimated Fair Value Per Share Results

As noted above, the hybrid method allocates the projected equity value to each share class at each potential future event date, taking into
consideration the rights and preferences of each class of equity and the anticipated timing of each event, and then discounts the results to present value using an appropriate risk adjusted discount rate. A discount for lack of marketability is then
applied, as the Company is a closely held, non-public company with no ready market for its shares, to arrive at an estimated fair value per share for each event. Finally, the estimated fair values per share
are probability weighted to arrive at a probability-weighted fair value per share.

 To derive its equity value in the Early IPO and Late
IPO scenarios, the Company relied upon an analysis of similarly situated comparable companies at the time of their IPOs. For the Stay Private scenario, the Company estimated an equity value by applying the Backsolve Method based on the
Company’s Series C Financing, which closed on October 8, 2019. After estimating the Company’s total equity value based on the sale price of the Company’s Series C Financing, that value was allocated to the various classes of the
Company’s equity using the OPM.

 The selection of the discount for lack of marketability was based on the Protective Put Method, a
method of estimating a discount for lack of marketability using the OPM as outlined in the AICPA Practice Guide. This method considers the duration of any restrictions or period of anticipated illiquidity in each of the IPO scenari